pSivida Corp. Announces First Quarter Fiscal 2015 Financial Results Release Date and Conference Call Information
October 31 2014 - 4:19PM
Business Wire
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the
development of sustained release, drug delivery products for
treating eye diseases, today announced that its financial results
for the first quarter of fiscal year 2015 will be released before
the market open on Friday, November 7, 2014. A conference call and
live webcast is scheduled for 8:30 a.m. ET that morning.
The conference call may be accessed by dialing (877) 312-7507
from the U.S. and Canada, or (631) 813-4828 from international
locations. A live webcast will be available on the Investor
Relations section of the corporate website at
http://www.psivida.com.
A replay of the call will be available beginning November 7,
2014, at approximately 11:30 a.m. ET and ending on November 14,
2014, at 11:59 p.m. ET. The replay may be accessed by dialing (855)
859-2056 within the U.S. and Canada or (404) 537-3406 from
international locations, Conference ID Number: 30044979. A replay
of the webcast will also be available on the corporate website
during that time.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, is a leader in
the development of sustained release, drug delivery products for
treating eye diseases. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core
technology systems, Durasert™ and Tethadur™. pSivida’s lead product
candidate, Medidur™ for treatment of the chronic, back-of-the-eye
disease posterior uveitis, is in a pivotal Phase III clinical
trial. Medidur uses the same injectable, sustained release
micro-insert as ILUVIEN® for the treatment of DME. ILUVIEN,
licensed to Alimera Sciences, is marketed in the U.K. and Germany
and has received or is pending marketing authorization in 15 other
EU countries for the treatment of chronic DME considered
insufficiently responsive to available therapies. In the U.S.,
ILUVIEN has been approved for the treatment of DME in patients who
have been previously treated with a course of corticosteroids and
did not have a clinically significant rise in intraocular pressure.
pSivida's FDA-approved Retisert®, an implant that provides
long-term, sustained drug delivery to treat posterior uveitis, is
licensed to and sold by Bausch & Lomb Incorporated. pSivida’s
pre-clinical research is focused on ocular and systemic delivery of
biologics and treatment of wet and dry age-related macular
degeneration, osteoarthritis and glaucoma.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties
and potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or
believe may occur in the future are forward-looking statements. The
following are some of the factors that could cause actual results
to differ materially from the anticipated results or other
expectations expressed, anticipated or implied in our
forward-looking statements: changes in actual capital requirements
to 2017; Alimera’s ability to finance, achieve additional marketing
approvals, obtain adequate pricing and reimbursement for,
successfully commercialize and achieve market acceptance of, and
generate revenues to pSivida from, ILUVIEN; FDA requirements with
respect to clinical trial data necessary to support an NDA for
Medidur; pSivida’s ability to finance, complete and achieve a
successful clinical outcome, file and achieve marketing approvals
for, Medidur for posterior uveitis; ability of Tethadur to
successfully deliver large biologic molecules; ability to develop
product candidates and products and potential related
collaborations; initiation and completion of clinical trials and
obtaining regulatory approval of product candidates; level of
continued sales of Retisert; adverse side effects; ability to
attain profitability; ability to obtain additional capital; further
impairment of intangible assets; fluctuations in operating results;
decline in royalty income; ability to, and to find partners to,
develop and market products; termination of license agreements;
competition and other developments affecting sales of products;
market acceptance; protection of intellectual property and avoiding
intellectual property infringement; retention of key personnel;
product liability; consolidation in the pharmaceutical and
biotechnology industries; compliance with environmental laws;
manufacturing risks; risks and costs of international business
operations; credit and financial market conditions; legislative or
regulatory changes; volatility of stock price; possible dilution;
absence of dividends; and other factors described in our filings
with the SEC. Given these uncertainties, readers are cautioned not
to place undue reliance on such forward-looking statements. Should
known or unknown risks materialize, or should underlying
assumptions prove inaccurate, actual results could differ
materially from past results and those anticipated, estimated or
projected in the forward-looking statements. Our forward-looking
statements speak only as of the dates on which they are made. We do
not undertake any obligation to publicly update or revise our
forward-looking statements even if experience or future changes
makes it clear that any projected results expressed or implied in
such statements will not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook:
https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog:
http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
In US:Martin E. Janis & Company, Inc.Beverly
JedynakPresident+1 312 943 1123M: +1 773 350
5793bjedynak@janispr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Sep 2023 to Sep 2024